Oncogenic KRAS mutations have been demonstrated to trigger a diverse range of phosphorylation cascades, including canonical MAPK, PI3K/AKT and RALGDS/RAL pathways, and inhibitors targeting these molecules have been utilized and combined in clinical practice to suppress these signaling cascades in colorectal cancer 54, 55. The gene discussed is KRAS; the disease is colorectal cancer.